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We assessed the prevalence, risk factors, and clinical
outcomes of patients co-colonized with vancomycin-resist-
ant enterococci (VRE) and methicillin-resistant
Staphylococcus aureus (MRSA) upon admission to the
medical and surgical intensive care units (ICUs) of a terti-
ary-care facility between January 1, 2002, and December
31, 2003. Co-colonization was defined as a VRE-positive
perirectal surveillance culture with an MRSA-positive ante-
rior nares surveillance culture collected concurrently.
Among 2,440 patients, 65 (2.7%) were co-colonized.
Independent risk factors included age (odds ratio [OR]
1.03, 95% confidence interval [CI] 1.01–1.05), admission to
the medical ICU (OR 4.38, 95% CI 2.46–7.81), male sex
(OR 1.93, 95% CI 1.14–3.30), and receiving antimicrobial
drugs on a previous admission within 1 year (OR 3.06, 95%
CI 1.85–5.07). None of the co-colonized patients would
have been identified with clinical cultures alone. We report
a high prevalence of VRE/MRSA co-colonization upon
admission to ICUs at a tertiary-care hospital. 
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
and vancomycin-resistant enterococci (VRE) cause
nosocomial infections and are associated with increased
rates of illness and death (1,2). Both organisms are now
endemic in many healthcare institutions, particularly in
intensive care units (ICUs) (3). Vancomycin is commonly
used to treat infections caused by MRSA; however, recent
emergence of S. aureus infections with high-level resist-
ance to vancomycin call into question the future effective-
ness of vancomycin for these nosocomial infections (4).
All known vancomycin-resistant S. aureus (VRSA) iso-
lates reported thus far have possessed the vanA gene,
which confers resistance to vancomycin and is believed to
have been acquired when an MRSA isolate conjugated
with a co-colonizing VRE isolate (5–10). Thus, patients
simultaneously co-colonized with MRSA and VRE are
likely at increased risk for colonization or infection by
VRSA.
Patients in the ICU and other critically ill patients are at
high risk for co-colonization with MRSA and VRE and,
possibly, VRSA, since both organisms are endemic and
associated with increased illness severity (11,12). Despite
the high risk, epidemiologic risk factors associated with
co-colonization by MRSAand VRE in patients admitted to
ICUs have not been described. In addition, previous stud-
ies in this population have been limited by the use of clin-
ical cultures as markers for colonization, which
underestimate the true proportion of patients colonized
with these resistant organisms (13–15).
To our knowledge, this study is the first to assess inde-
pendent risk factors and outcomes for patients co-colo-
nized with VRE and MRSA. The aim of this study was to
estimate the prevalence, risk factors, and clinical outcomes
of patients who are co-colonized by VRE and MRSAupon
admission to the medical and surgical ICUs of a tertiary-
care facility.
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Study Design and Patient Population
This study was approved by the institutional review
board of the University of Maryland, Baltimore. This study
utilized a prospective cohort of adult patients admitted to
the medical ICU (MICU) and surgical ICU (SICU) of the
University of Maryland Medical Center (UMMC) between
January 1, 2002, and December 31, 2003. UMMC is a ter-
tiary-care facility in Baltimore, Maryland. The MICU is a
10-bed, private room unit providing care to patients who
have acute or potentially life-threatening medical condi-
tions including hematologic and other malignancies. The
SICU is a 19-bed, private room unit providing care to adult
patients with solid organ transplantation and abdominal,
genitourinary, orthopedic, and otolaryngologic surgery.
During the study period, routine surveillance cultures
of the anterior nares for MRSAand perirectal area for VRE
were obtained from patients within 48 hours of admission
to both ICUs for infection control purposes. Cultures were
obtained from an average of 80% of admitted patients.
Patients from whom both cultures were not obtained upon
ICU admission or had an ICU length of stay <5 hours were
excluded. Patients may have had multiple admissions dur-
ing the study period, and all eligible admissions were
included in this analysis.
Data Collection and Variables
All data were abstracted from the UMMC central data
repository that contains the patients’ electronic medical
records. The validity of these data was assessed by ran-
domly sampling 10% of the patients’ electronic data
records and comparing them to the original paper medical
records. The positive and negative predictive values of this
assessment exceeded 99% for both validity measures,
which was similar to values seen in previous studies with
this same data source (16–19).
Co-colonization by VRE and MRSA upon ICU admis-
sion was defined as a positive surveillance culture of the
perirectal area for VRE and a positive surveillance culture
of the anterior nares for MRSA within 48 hours of admis-
sion to either the MICU or SICU. All coexisting conditions
were defined by using International Classification of
Diseases, 9th Revision and the Charlson Comorbidity
Index (20).
Laboratory Methods 
All media and reagents were from BD Biosciences (San
Jose, CA, USA) unless otherwise noted. S. aureus was iso-
lated from both anterior nares and perirectal cultures.
Nares swabs were plated on tryptic soy agar with 5% sheep
blood to isolate S. aureus. Plates were examined at 24 and
48 hours for creamy, golden β-hemolytic colonies typical
of S. aureus. Perirectal swabs were plated on both tryptic
soy agar with 5% sheep blood and phenylethyl alcohol
agar (Remel, Lenexa, KS, USA) and cultured in Baird
Staphylococcus Enrichment broth (Merck, Darmstadt,
Germany). Presumptive S. aureus colonies were confirmed
by positive catalase and Murex Staphaurex (Remel) reac-
tions. MRSAwere identified by growth on Mueller Hinton
agar with 4% NaCl and 6 µg/mL oxacillin. 
Enterococci were isolated by plating perirectal swabs
on Columbia Modified CNA agar and examined at 24 and
48 hours. Presumptive enterococci colonies that were
gram-positive cocci, catalase negative, and pyrrolidonyl-
β-naphthylamide positive were plated on vancomycin
screening agar and motility agar. Vancomycin-resistant,
nonmotile enterococci were identified as VRE.
Statistical Analyses
Three risk factor analyses were conducted: 1)
VRE/MRSA co-colonized patients were compared to all
other ICU patients, 2) patients colonized with VRE alone
were compared to patients not colonized with VRE, and 3)
patients colonized with MRSA alone were compared to
patients not colonized with MRSA. Patients co-colonized
with MRSA or VRE were excluded for analyses 2 and 3
above that compared solitary VRE or MRSA colonization
to noncolonized patients. 
Student t, chi-square, Fisher exact, and Wilcoxon rank
sum tests were used for descriptive analyses to assess
bivariable differences between groups. All variables that
were significant (α = 0.1) in the bivariable analyses were
included in the initial (full) multivariable logistic regres-
sion model. In each of the multivariable analyses per-
formed, variables not significantly associated (α = 0.05)
with the outcome (VRE/MRSA co-colonization and VRE
or MRSAsolitary colonization upon admission to the ICU)
were removed from the model. Each of the removed vari-
ables was then reinserted into the model to assess if its
presence altered the regression coefficient by >20%. If so,
this risk factor was included in the final model. The result-
ing multivariable logistic regression model was considered
the final model and was used to calculate odds ratios and
95% confidence intervals for the remaining risk factors. 
Differences in patients’ clinical outcomes after assess-
ing colonization status were also assessed. These variables
included length of stay after the ICU admission culture,
subsequent positive clinical cultures for VRE or MRSA,
in-hospital death rate, and readmission to the index hospi-
tal or transfer to another healthcare facility. Subsequent
positive clinical cultures were limited to sterile sites, and
thus only blood, cerebrospinal fluid, or urine cultures were
considered. 
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During the 2-year cohort period (January 1,
2002–December 31, 2003), 3,090 patients were admitted
to the MICU or SICU for a >5-hour stay. Of these, 2,440
patients (79.0%) had both anterior nares and perirectal
admission cultures collected. Sixty-five patients (2.7%)
were co-colonized with VRE and MRSA, 247 patients
(10.1%) were colonized with VRE alone, and 175 patients
(7.2%) were colonized with MRSA alone. Of the 57
MRSA/VRE co-colonized patients with perirectal samples
available for additional analysis, 23 patients (40.4%) were
perirectally colonized with MRSA in addition to perirectal
VRE and MRSA nasal colonization. Results of the bivari-
able analyses for VRE/MRSA co-colonization are dis-
played in Table 1. Because of space constraints, bivariable
results for colonization by MRSA or VRE alone are not
shown. These results suggest that patients colonized with
VRE, MRSA, or both were significantly more likely to
have been admitted to the MICU, have had previous hos-
pital admissions, and have antimicrobial exposures within
1 year of current admission (p<0.05 for all). Among co-
colonized patients, 58% had been admitted to the index
hospital in the previous year, and 51% had received
antimicrobial drugs during an admission in the previous
year. In addition, ≈48% of MRSA/VRE co-colonized
patients had a previous positive culture (clinical or surveil-
lance) for MRSA before the study period, and ≈28% had a
previous positive culture for VRE.
Independent risk factors identified with logistic regres-
sion for the different colonization states (co-colonization,
VRE only, or MRSA only) were markedly different
(Table 2). Table 3 displays clinical outcomes of
VRE/MRSA co-colonized patients. Approximately 25%
percent of co-colonized patients died during the current
admission; however, mortality was not significantly high-
er compared to non–co-colonized patients (p = 0.15).
Three percent of co-colonized patients had MRSA-posi-
tive clinical cultures, and 3% of co-colonized patients had
VRE-positive clinical cultures on the current or subse-
quent admissions (within 6 months). None of the co-colo-
nized patients had clinical cultures positive for both
organisms. Thirty-two percent of VRE/MRSA co-colo-
nized patients were transferred to another hospital upon
discharge from the index hospital compared with 15% of
non–co-colonized patients (p<0.01).
Discussion
Increasing VRSA prevalence in the healthcare setting
Resistant Staphylococcus aureus and Enterococci
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 10, October 2005 1541could result in considerable illness and death (21). To our
knowledge, we present the first estimates of the preva-
lence, risk factors, and clinical outcomes of patients with
VRE and MRSA co-colonization. As has been previously
reported, co-colonization with VRE and MRSAhas always
preceded VRSA colonization or infection, and patients
admitted to ICUs are likely a high-risk population
(11–13,15). We show that among patients who had admis-
sion cultures taken, 4.6% admitted to the MICU and 1.2%
admitted to the SICU of a tertiary-care facility during a 2-
year period were co-colonized with MRSAand VRE, with
an overall co-colonization proportion of 3% in both ICUs
together. In addition, the observation that ≈40% of
MRSA/VRE co-colonized patients were perirectally colo-
nized with both organisms suggests the potential risk for
the exchange of genetic material, which could result in the
emergence of VRSA.
None of the 65 VRE/MRSA–co-colonized patients had
positive clinical cultures for both VRE and MRSA on cur-
rent or subsequent admissions to the index hospital. Thus,
none would have been identified as co-colonized without
the active surveillance culturing program in place at our
institution. As has been suggested by previously reported
cases of VRSA, early identification of these patients is rec-
ommended to minimize antimicrobial selective pressure
and enhance infection control efforts to reduce the poten-
tial for patient-to-patient transmission (5,7).
In this study, <25% of co-colonized patients died, and
nearly 35% were discharged to other hospitals or rehabili-
tation facilities, where the risk of transmitting these organ-
isms to other patients is substantial. Considering the
potential for colonization, infection, and transmission of
VRSA, treating physicians, hospital staff, and infection
control personnel at receiving institutions must be ade-
quately prepared to isolate and treat these patients (22,23).
Previous studies of transmission from vancomycin-inter-
mediate S. aureus (VISA)- or VRSA-colonized or infected
patients show that these organisms can be transmitted to
close contacts or other hospitalized patients (7,21,24).
Previous studies have also shown that carriage of VRE
or MRSA may be persistent, which would increase the
potential for co-colonized patients to transmit either or
both of these organisms to other patients (25,26). A math-
ematical model of the transmission dynamics of VRE has
suggested that persistent colonization is the most impor-
tant factor for increasing the endemic prevalence of this
organism in the hospital (26). Furthermore, the potential
for prolonged co-colonization could increase the likeli-
hood that these patients would experience sufficient selec-
tive pressure for emergence of VRSA. 
Recent reviews by Reuf, Fridkin, and Cosgrove et al.
have summarized risk factors associated with clinical cul-
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with only 3 reported cases of VRSA and ≈20 reported
cases of VISA, the precision of statistical associations has
been limited. Recent exposure to vancomycin and recent
isolation of MRSAwere identified as risk factors for VISA
in addition to concurrent colonization or infection with
VRE and MRSA. Among co-colonized patients in this
study,  ≈21% received vancomycin, 26% received
piperacillin-tazobactam, and 17% received a fluoro-
quinolone before culture results.
This study is the first to report the prevalence, risk fac-
tors, and clinical outcomes of patients with VRE/MRSA
co-colonization upon admission to the ICU. We report sev-
eral risk-factors for co-colonization, including that the
odds of co-colonization for patients admitted to the MICU
were >4 times greater than those of patients admitted to the
SICU and that patients who received antimicrobial drugs
within 1 year of admission had 3 times the odds of co-col-
onization as patients who had not received antimicrobial
drugs during a previous admission. 
Ray et al. assessed the prevalence of gastrointestinal S.
aureus colonization among a convenience sample of 37
patients colonized with VRE and reported that 20 (54.1%)
of these patients were also colonized with MRSA (27).
However, comparing these results to those presented here
is difficult, given the stark differences between patient
groups. The study by Ray et al. included only hospitalized
patients from whom a minimum of 3 stool samples (col-
lected weekly) were obtained (i.e., inpatients with extend-
ed lengths of stay). We believe that ICU patients
co-colonized with VRE and MRSAare at risk of acquiring
and transmitting VRSA because they generally are
exposed to greater antimicrobial selective pressure, have
extended lengths of stay, greater likelihood of indwelling
devices, greater severity of illness, and are more likely to
have a history of previous hospitalization and related expo-
sures than patients admitted to general medical wards.
Despite these differences, perirectal colonization of both
organisms was similar between the patients in the study by
Ray et al. and this study (54.1% vs. 40.3%, respectively).
Other studies have also suggested a prevalence of
VRE/MRSA co-colonization or co-infection ranging from
9.5% to 28.6%; however, these studies relied upon clinical
cultures to provide these estimates (14,15).
A limitation of this study is that investigators were
unable to determine the species of the VRE isolates.
Historically, Enterococcus faecalis has been more likely
to be associated with conjugation events and subsequent
VRSA colonization or infection compared with E. faeci-
um (7,28). However, only 3 VRSA cases are known, and
we are not aware of any biologic explanation for why E.
faecium would be less likely to be involved in transmis-
sion of vancomycin resistance to MRSA compared with
E. faecalis. Still, these data would have been useful and
informative. A previous, hospitalwide study at UMMC
suggested that among isolated VRE, the prevalence of E.
faecium and E. faecalis were 87%, and 13%, respectively
(29).
In summary, these data describe a high prevalence of
patients co-colonized with VRE and MRSA on admission
to an ICU at a tertiary-care hospital, none of whom would
have been detected by clinical culture. Risk factors for
VRE and MRSAco-colonization are also described. Given
that many of these patients were discharged to other insti-
tutions, treating physicians and infection control personnel
must be cognizant of the risks for VRSA colonization and
infection and use appropriate precautions. Appropriate
methods to rapidly detect co-colonized patients must be
identified to suppress the emergence of VRSA; limit
patient-to-patient transmission of MRSA, VRE, and
VRSA; and prevent endemic VRSAcolonization in health-
care institutions.
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